arrow
W

Won Young Tak

Kyungpook National University
H指数:56
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discordant Antitumor Efficacy with Compromised Survival in High-Risk Unresectable Hepatocellular Carcinoma

高风险不可切除肝细胞癌中不一致的抗肿瘤疗效与受损的生存期

Cancers
IF4.4
2026-09-110
OA
Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial

Elbsiran和PEG-IFNα用于慢性乙型肝炎感染:一项部分随机、开放标签、II期试验

2025-11-070
OAAI
Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C

口服抗病毒药物后肝脏硬度测量可有效预测慢性丙型肝炎患者发生HCC的风险

2025-09-080
OAAI
A serum exosomal microRNA-based artificial intelligence diagnostic model for highly accurate detection of hepatocellular carcinoma

一种基于血清外泌体微小RNA的人工智能诊断模型,用于高度准确地检测肝细胞癌

2025-06-260
OAAI
Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)

索磷布韦为基础治疗慢性丙型肝炎患者后的长期肝脏及肝外结局(LONGHEAD研究)

2025-04-100
OA
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB
2024-12-010
PRE
Aspartate aminotransferase-to-platelet ratio index outperforms Fibrosis-4 in 2843 Korean patients with metabolic dysfunction-associated steatotic liver disease

在2843例韩国代谢功能障碍相关的脂肪性肝病患者中,天冬氨酸转氨酶与血小板比率指数优于纤维化4

2024-11-290
PRE
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial

阿特珠单抗联合贝伐单抗与主动监测在切除或消融高危肝细胞癌患者中的比较 (IMbrave050): 一项随机、开放标签、多中心、3期试验

LANCET
IF88.5
2023-11-01144
PRE
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials
2023-01-0111
OAAI